SCHEMBL5446647

SCHEMBL5446647

CCN(CC)c1nc(Nc2cccc(Cl)c2)nc(N2CCN(c3ncccc3Cl)CC2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 2/20 0.48
MALT1 Q9UDY8 1/20 0.46
GBA1 P04062 1/20 0.46
PIK3CA P42336 1/20 0.44
MTOR P42345 1/20 0.44
JAK3 P52333 1/20 0.44
NTRK2 Q16620 1/20 0.44
CAMK2A Q9UQM7 1/20 0.44
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
ATM Q13315 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TRPA1 O75762 1/20 0.41
EGFR P00533 1/20 0.40
TERT O14746 1/20 0.40
CHEK1 O14757 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5449419 0.91 CFTR (0.47) CFTRNTRK2TERTCHEK1HTT
SCHEMBL5448937 0.89 GBA1 (0.48) MALT1GBA1PIK3CACHEK1HTT
SCHEMBL5445745 0.89 MALT1 (0.42) CFTRMALT1TERT
SCHEMBL5441116 0.86 MEN1 (0.48) CFTRNPSR1HTT
SCHEMBL5451387 0.84 CTSL (0.45) NPSR1HTT
SCHEMBL5449029 0.83 POLB (0.43) CFTRNTRK2CHEK1HTTSCN9A
SCHEMBL5451317 0.82 PIK3CA (0.66) MALT1GBA1PIK3CAMTORJAK3
SCHEMBL5449391 0.81 POLB (0.41) CFTRNTRK2CHEK1
SCHEMBL5442108 0.80 CTSL (0.44) LMNACHEK1HTTSCN9A
SCHEMBL5451291 0.80 TRPV1 (0.46) CFTRMALT1TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043049-A1 Substituted heterocyclic diarylamine analogues NEUROGEN CORPORATION (US) 2007-02-22 US claimed
EP-1651636-A1 SUBSTITUTED HETEROCYCLIC DIARYLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2006-05-03 EP claimed
WO-2005007646-A1 SUBSTITUTED HETEROCYCLIC DIARYLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2005-01-27 WO claimed
US-20070043049-A1 Substituted heterocyclic diarylamine analogues NEUROGEN CORPORATION (US) 2007-02-22 US disclosed
US-20070043049-A1 Substituted heterocyclic diarylamine analogues NEUROGEN CORPORATION (US) 2007-02-22 US disclosed
US-20070043049-A1 Substituted heterocyclic diarylamine analogues NEUROGEN CORPORATION (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043049-A1 Substituted heterocyclic diarylamine analogues GPR35, NPY1R, BDKRB1 CFTR 1398/4885MALT1 704/4885GBA1 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.